Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’s Luxturna Deal Expands Gene Therapy Ambitions

Executive Summary

By licensing Spark Therapeutics' Luxturna outside the US, Novartis is expanding its gene therapy ambitions into in vivo and non-oncological treatments.

You may also be interested in...



Luxturna Approved In EU: Novartis Outlines Lessons For Gene Therapy Strategies

The European Commission has officially approved Luxturna, Novartis/Spark Therapeutics’ transformative gene therapy. The Swiss firm tells Scrip how the lessons it expects to learn from launching its first gene therapy will inform its future strategy in this new field.

Eight Things To Know From Novartis' Third Quarter Call

The company's $2.1bn acquisition of Endocyte and expansion into radiopharmaceuticals dominated some of the call, but with the launches of drugs like Cosentyx, Kymriah, Kisqali and Aimovig underway, there was a lot for Novartis' management team to address.

Novartis Sees The Light And Plumps For Alcon Spin-Off

Having acquired Alcon for an eye-watering $52bn seven years ago, the Swiss major has decided that spinning off the eyecare business which has finally returned to growth (but is worth about half what Novartis paid in 2011) makes the most sense as it becomes a company even more focused on pharma.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142209

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel